Revenue Showdown: TG Therapeutics, Inc. vs Travere Therapeutics, Inc.

Biotech Revenue Battle: TG vs Travere

__timestamp	TG Therapeutics, Inc.	Travere Therapeutics, Inc.
Wednesday, January 1, 2014	152381	28203205
Thursday, January 1, 2015	152381	99892000
Friday, January 1, 2016	152381	133591000
Sunday, January 1, 2017	152381	154937000
Monday, January 1, 2018	152000	164246000
Tuesday, January 1, 2019	152000	175338000
Wednesday, January 1, 2020	152000	198321000
Friday, January 1, 2021	6689000	227490000
Saturday, January 1, 2022	2785000	212018000
Sunday, January 1, 2023	233662000	145238000

Unleashing insights

Revenue Showdown: TG Therapeutics vs Travere Therapeutics

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, TG Therapeutics, Inc. and Travere Therapeutics, Inc. have been on distinct trajectories. From 2014 to 2023, Travere Therapeutics consistently outperformed TG Therapeutics in revenue, peaking in 2021 with a 700% increase from 2014. Meanwhile, TG Therapeutics saw a dramatic surge in 2023, with revenues skyrocketing by over 15,000% compared to 2020, marking a significant turnaround. This shift highlights the volatile nature of the biotech industry, where strategic decisions and market conditions can lead to rapid changes in financial performance. As we look to the future, the question remains: will TG Therapeutics maintain its newfound momentum, or will Travere reclaim its lead?

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025